Bavarian Nordic’s RSV Vaccine Candidate Granted PRIME Eligibility
June 30, 2022
The PRIME scheme helps accelerate assessment by the European Medicines Agency for therapeutics that treat otherwise unmet medical needs. Bavarian Nordic has been given access to the PRIME scheme for its respiratory syncytial virus (RSV) vaccine for people 60 and over, for whom the disease can be life-threatening.
According to , “Results from Bavarian Nordic’s phase 2 trial, which enrolled healthy adult volunteers aged 18-50 years, showed a significant reduction in viral load in MVA-BN RSV vaccinated subjects compared to placebo. The vaccinated subjects also showed a significant reduction in clinical symptoms typically associated with RSV infections.”
To read more, click here.
(Source: PM Live, June 30th, 2022)